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Abstract
Background and Aims: There is paucity of data on safety and efficacy of anti-tumour necrosis 
factor [TNF] in elderly inflammatory bowel disease [IBD] patients. We aimed to compare the long-
term treatment failure rates and safety of a first anti-TNF agent in IBD patients between different 
age groups [<40 years/40–59 years/≥60 years].
Methods: IBD patients who started a first anti-TNF agent were identified through IBDREAM, a 
multicentre prospective IBD registry. Competing risk regression was used to study treatment 
failure, defined as time to drug discontinuation due to adverse events [AEs] or lack of effectiveness, 
with discontinuation due to remission as a competing risk.
Results: A total of 895 IBD patients were included; 546 started anti-TNF at age <40 [61.0%], 268 
at age 40–59 [29.9%], and 81 at age ≥60 [9.1%]. Treatment failure rate was higher in the two older 
groups (subhazard rate [SHR] age ≥60 1.46, SHR age 40–59 1.21; p = 0.03). The SHR in the elderly 
[>60] was 1.52 for discontinuation due to AEs and 1.11 for lack of effectiveness. Concomitant 
thiopurine use was associated with a lower treatment failure rate (SHR 0.78, 95% confidence 
interval [CI] 0.62–0.98, p = 0.031). Serious adverse event [SAE] rate, as well as serious infection 
rate, were significantly higher in elderly IBD patients [61.2 versus 16.0 and 12.4 per 1000 patient-
years, respectively] whereas the malignancy rate was low in all age groups.
Conclusions: Elderly IBD patients starting a first anti-TNF agent showed higher treatment failure 
rates, but concomitant thiopurine use at baseline was associated with lower failure rates. Elderly 
IBD patients demonstrated higher rates of SAEs and serious infections.











trecht user on 17 M
ay 2021
1. Introduction
The global increase in life expectancy as well as inflammatory bowel 
disease [IBD] incidence is resulting in more elderly IBD patients.1 
IBD therapies in this group of patients can be challenging due to age-
specific risks such as infections and malignancies. Current guidelines 
do not advise different treatment strategies in elderly IBD patients. 
However, elderly patients are under-represented in clinical studies 
and there are limited data in elderly patients to guide clinical deci-
sion making.2,3
Although anti-tumour necrosis factor [TNF] therapy is ef-
fective as both induction and maintenance therapy in IBD pa-
tients, the immunosuppressive effects are associated with adverse 
events [AEs].4,5 These events include [opportunistic] infections, 
non-melanoma skin cancer, lymphoma, and melanoma, espe-
cially in combination with immunosuppressive therapies including 
thiopurines.2,6,7 Since the general risk of infections and malignan-
cies increases with age, the safety of anti-TNF therapy in elderly 
IBD patients is debated and may affect treatment choices in this 
specific age group.8
Current evidence points towards a possible increase in AEs 
in elderly IBD patients on anti-TNF therapy, although data are 
scarce.9 For example, a cohort study reported more severe infec-
tions in 95 IBD patients aged >65 years treated with anti-TNF.10 
However, nearly all patients in the latter study used corticoster-
oids at baseline, which may have influenced infection rates and is 
not representative of current practice. Furthermore, it is unknown 
if treatment failure rates [defined as rates of stopping anti-TNF 
due to AEs or lack of efficacy] are equal in elderly compared with 
younger IBD patients. Two small retrospective studies from tertiary 
centres reported higher discontinuation rates in elderly patients on 
anti-TNF.11,12 However, results from current studies are difficult to 
interpret, since stopping anti-TNF due to remission is regarded as 
anti-TNF discontinuation as well. In fact, when discontinuation 
rates are used as a proxy for treatment failure, stopping anti-TNF 
due to ‘stable remission’ should be regarded as a competing risk 
instead of an event.
As evidence is scarce, more real-world data are needed on anti-
TNF agents in elderly IBD patients. For this purpose, we used 
IBDREAM, a large multicentre prospective IBD registry in The 
Netherlands. The aim of this study was to compare the safety and the 
treatment failure rates of the first anti-TNF therapy in IBD patients 
between specific age groups [<40, 40–59, and ≥60 years]. Second, we 
aimed to identify baseline variables associated with anti-TNF treat-
ment failure due to AEs or lack of effectiveness.
2. Materials and Methods
2.1. Study design
We compared the treatment failure rates of the first treatment with 
anti-TNF therapy between different age groups in a large multicentre 
IBD cohort. Risk factors for discontinuation due to AEs or lack of 
effectiveness were identified.
2.2. Registry and cohort
Data were derived from IBDREAM, a large multicentre pro-
spective IBD registry in The Netherlands. IBDREAM collects med-
ical data in a prospective and systematic fashion from IBD patients 
in four non-academic hospitals and one academic hospital in The 
Netherlands [Jeroen Bosch Hospital, s’-Hertogenbosch; Onze 
Lieve Vrouwe Gasthuis, Amsterdam; Medical Spectrum Twente, 
Enschede; Franciscus Gasthuis & Vlietland, Rotterdam; and 
Radboud University Medical Centre, Nijmegen]. After inclusion in 
IBDREAM, patients’ demographic data, disease activity, previous 
and current medication use, previous serious adverse events [SAEs], 
hospitalisations, and IBD surgery are registered in IBDREAM. 
Subsequently, follow-up data are prospectively collected during 
routine clinical visits.
In the current study, we included all patients with an established 
diagnosis of Crohn’s disease [CD], ulcerative colitis [UC], or IBD 
unclassified [IBD-U] who used or are using anti-TNF therapy. We de-
fined three groups of IBD patients based on their age at the moment 
of their first anti-TNF treatment: <40, 40–59, and ≥60  years. We 
defined ‘elderly’ as patients aged ≥60 years, as previously published 
by multiple research groups.9,13,14
2.3. Data collection
For this study, data on demographics, medical history, concomitant 
IBD medication use at start of anti-TNF, reasons for discontinuation, 
and serious adverse events [SAEs] were extracted from IBDREAM. 
SAEs included hospital admission due to disease activity or side 
effects, infections, allergic reactions, IBD-related surgery, or malig-
nancies. Data were retrieved from IBDREAM on August 1, 2018. 
Follow-up was defined as years from start of first anti-TNF agent 
until date of data extraction.
2.4. Outcomes
Primary outcomes of this study were the anti-TNF treatment failure 
rate and the SAE rate during the first anti-TNF therapy. Drug sur-
vival was used as proxy for treatment failure; it was calculated by 
measuring years of anti-TNF treatment until discontinuation due 
to [serious] AEs or lack of effectiveness, corrected for remission 
as a competing risk. Lack of effectiveness was defined as either 
lack of initial clinical response [primary non-response] or loss of 
response, resulting in a switch of therapy or surgery. Regarding 
safety, SAE rates including serious infection rates (events per 1000 
patient-years [py]) were compared between the age groups. Serious 
infections were defined as infections requiring hospitalisation. 
Second, factors associated with treatment failure were identified. 
We included gender, disease duration, IBD -type [UC versus CD], 
anti-TNF agent [infliximab or adalimumab], concomitant IBD 
medication use at baseline [5-aminosalicylic acid, methotrexate, 
thiopurine, prednisone], malignancy, and previous IBD surgery in 
our analysis. In addition, we identified factors associated with dis-
continuation due to AEs alone and discontinuation due to lack of 
effectiveness alone.
2.5. Statistical methods
We used STATA 11.2’s competing risk regression based on Fine and 
Gray’s proportional subhazards model to study time to treatment 
failure, with discontinuation due to remission as a competing risk. 
Patients lost to follow-up or stopping anti-TNF for other reasons 
[e.g. pregnancy] were censored at the moment of cessation of 
therapy. End of follow-up was defined as date of stopping anti-TNF 
or date of data extraction. We performed separate competing risk 
analyses for discontinuation due to AEs alone and discontinuation 
due to lack of effectiveness alone. For the analysis of discontinuation 
due to AEs, stopping due to lack of effectiveness was regarded as a 
competing risk as well. Likewise, stopping due to AEs was regarded 
as a competing risk in the analysis of discontinuation due to lack of 
effectiveness. Wald tests were used to determine the significance of 
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variables included in the competing risks model. Age group was ini-
tially treated as a categorical covariate, and was simplified to a linear 
effect between categories when appropriate.
Descriptive statistics were used to describe the number of IBD-
related hospitalisations, IBD-related surgeries, and malignancies. 
Outcomes with a normal distribution were presented as means with 
standard deviation [SD]; non-normally distributed outcomes were 
presented as medians with interquartile range [IQR]. Pearson’s chi 
square test was used for binominal variables in the three age groups, 
and Fisher’s exact test if numbers were <5. The Kruskal-Wallis test 
was used for continuous non-normally distributed variables in the 
three age groups. To demonstrate the difference between the com-
peting risk model and the overall discontinuation rate [i.e. the cu-
mulative incidence for patients stopping anti-TNF], a Kaplan-Meier 
[KM] curve [with log-rank test] was used. Thus, in the KM curve, all 
reasons for discontinuation [including remission] were counted as an 
event and patients were censored at end of follow-up. Poisson regres-
sion analysis was used to compare SAE rates. A p-value <0.05 was 
considered statistically significant. SPSS Statistics [IBM, version 25] 
and STATA 11.2 were used for statistical analyses.
2.6.  Ethics
This study and the IBDREAM registry were approved by the 
Radboudumc Medical Ethical Committee [2015–2245]. All partici-
pants signed written informed consent.
3. Results
3.1. Patients
A total of 895 IBD patients with a history of at least one anti-TNF 
agent were identified. Baseline characteristics are shown in Table 1. 
The majority of IBD patients had CD [679 patients, 75.9%], 200 
patients had UC [22.3%], and 16 had IBD-U [1.8%]. Males rep-
resented 42.2% of the cohort, and the median age at IBD diag-
nosis was 26 years [IQR 19–38]. Median follow-up since start of 
the first anti-TNF was 46  months [IQR 18–97]. In 546 patients 
[61.0%] the first anti-TNF therapy was started at age <40, 268 
patients started at age 40–59 [29.9%], and 81 at age ≥60 [9.1%]. 
Infliximab was the first anti-TNF therapy in 74.5%, 71.3%, and 
66.7% of patients, respectively, per age group, p = 0.258. Of the 
81 patients who started anti-TNF therapy at age ≥60, 37 [45.7%] 
patients were ≥60  years at moment of IBD diagnosis. Patients 
who started the first anti-TNF at age <40 had a median disease 
duration of 2 years, versus 7.5 years in the older patient groups 
[p <0.001]. Furthermore, a higher UC versus CD rate was observed 
in the ≥60 group [32.1% versus 18.5% and 27.2 %, p = 0.002]. 
Co-medication use at baseline was not significantly different be-
tween the different age groups, except for thiopurines that were 
used less in the older patient groups. At the moment of initiation of 
anti-TNF therapy, immunosuppressive therapy was used in 64.8%, 
57.8%, and 63.0% of patients [p = 0.150], including thiopurine 
in 50.2%, 41.0%, 34.6% [p = 0.005] and prednisone in 24.2%, 
Table 1.  Baseline characteristics.
All patients  
[n = 895]
1st anti-TNF < 40  
[n = 546]
1st anti-TNF  
4059  
[n = 268] 
1st anti-TNF ≥ 60  
[n = 81] 
p-value
Age at start 1st anti-TNF, median [IQR] 34.2 [24.1–48.3] 26.4 [11.5] 48.8 [9.2] 67.1 [8.3] -
Disease duration in years, median [IQR] 3.0 [1.0–10.0] 2.0 [5.0] 7.5 [19.0] 7.5 [23.3] 0.000*
Follow-up since start 1st anti-TNF, months, 
median [IQR]
46 [18–97] 55 [23–103] 36 [17–87] 19 [9–48] 0.000*
Gender: male, n [%] 378 [42.2] 209 [38.3] 139 [51.9] 30 [37.0] 0.001*
IBD type, n [%]      
- Crohn’s disease 679 [75.9] 436 [79.9] 190 [70.9] 53 [65.4] 0.001*
- Ulcerative colitis 200 [22.3] 101 [18.5] 73 [27.2] 26 [32.1] 0.002*
- IBD-U 16 [1.8] 9 [1.6] 5 [1.9] 2 [2.5] 0.735
1st anti-TNF, n [%]      
- Infliximab 652 [72.8] 407 [74.5] 191 [71.3] 54 [66.7] 0.258
- Adalimumab 243 [27.2] 139 [25.5] 77 [28.7] 27 [33.3] 0.258
Medical history, n [%]      
- PSC 8 [0.9] 7 [1.3] 0 [0.0] 1 [1.2] 0.178
- Prior IBD-surgery 154 [17.2] 72 [13.2] 64 [23.9] 18 [22.2] 0.000*
- Prior malignancy 13 [1.5] 2 [0.4] 2 [0.7] 9 [11.1] 0.000*
- BCC/SCC 8 [0.9] 0 [0.0] 5 [1.9] 3 [3.7] 0.000*
Mesalamine at baseline, n [%]      
- 5-ASA oral 123 [13.7] 69 [12.6] 41 [15.3] 13 [16.0] 0.486
Immunosuppressives at baseline, n [%]      
- Prednisone 210 [23.5] 132 [24.2] 56 [20.9] 22 [27.2] 0.420
- Prednisone alonea 91 [10.2] 55 [10.1] 23 [8.6] 13 [16.0] 0.147
- Budesonide 72 [8.0] 39 [7.1] 22 [8.2] 11 [13.6] 0.143
- Methotrexate 31 [3.5] 15 [2.7] 12 [4.5] 4 [4.9] 0.261
- Thiopurine 412 [46.0] 274 [50.2] 110 [41.0] 28 [34.6] 0.005*
- No immunosuppressivesb 335 [37.4] 192 [35.2] 113 [42.2] 30 [37.0] 0.150
Bold entries are significant p-values. IQR, interquartile range; n, number; TNF, tumour necrosis factor; IBD, inflammatory bowel disease; IBD-U, inflammatory 
bowel disease unclassified; PSC, primary sclerosing cholangitis; BCC, basal-cell carcinoma; SCC, squamous cell carcinoma; 5-ASA, 5-aminosalicylic acid.
aNo thiopurine or methotrexate.
bNo thiopurine, methotrexate, prednisone, or budesonide.
*A p-value <0.05 was considered statistically significant
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20.9%, and 27.2%, of patients aged <40, 40–59, and ≥60, respect-
ively [p = 0.420].
3.2. Reasons for discontinuation
Of 895 IBD patients, 450 discontinued therapy [50.3%] during 
follow-up. The drug survival after 6  months was 84.3%, 81.6%, 
and 71.8% in patients aged <40, 40–59, and ≥60, respectively, and 
76.4%, 72,8%, and 66.3% after 12  months. Remission was the 
reason for stopping in 15.1%, 13.5%, and 3.0% of patients aged 
<40, 40–59, and ≥60 years, respectively. The main reasons for stop-
ping anti-TNF in elderly patients were AEs in 39.4% and lack of 
effectiveness in 42.4% of patients who discontinued [Table 2]. In pa-
tients aged <40 and 40–59, the main reason for discontinuation was 
lack of effectiveness [40.5% and 47.4%, respectively]. In these pa-
tient groups, AEs were the reason for stopping in respectively 27.1% 
and 28.6% of patients who discontinued anti-TNF.
3.3. Competing risk models
3.3.1. Treatment failure
We analysed the probability of treatment failure by a competing-
risks regression analysis, with discontinuation due to AEs or lack 
of effectiveness as the outcome of interest and discontinuation due 
to remission as a competing event. Overall, age was associated with 
a higher discontinuation rate [p = 0.03 Figure 1], with a subhazard 
rate [SHR] for discontinuation of 1.23 (95% confidence interval [CI] 
0.96–1.56) in the 40–59 group and 1.46 [95% CI 0.94–2.20] in the 
≥60 group, both compared with the <40 group. Thiopurine use at 
baseline was associated with a lower rate of treatment failure, re-
gardless of age [SHR 0.78, 95% CI 0.62–0.98, p = 0.031]. Neither 
prednisone use nor methotrexate use was associated with a higher 
rate of treatment failure in the entire cohort. However, the subgroup 
of patients who only used prednisone in addition to anti-TNF, but 
without thiopurines or methotrexate at baseline, did have a higher 
risk of treatment failure [SHR 1.45, 95% CI 1.02–2.04, p = 0.037; 
Supplementary Table A, available as Supplementary data at ECCO-
JCC online].
Supplementary Figure A, available as Supplementary data at 
ECCO-JCC online, demonstrates the analysis without competing 
risk [thus, remission was included as a reason for discontinuation 
instead of a competing risk for treatment failure]. In this analysis, no 
statistically significant difference in time to drug discontinuation was 
detected between age groups [log-rank test].
3.3.2. Discontinuation due to AEs
The difference in discontinuation rates due to AEs between the 
three age groups did not reach statistical difference, with an SHR 
of 1.07 [95% CI 0.73–1.58] in the 40–59 group and 1.52 [95% CI 
0.83–2.76] in the ≥60 group, compared with the youngest group 
[Figure 2a]. Concomitant prednisone use was not associated with a 
higher rate of discontinuation due to AEs, except for the subgroup 
of patients who only used prednisone in addition to anti-TNF, but 
without thiopurines or methotrexate at baseline [SHR 2.09, 95% CI 
1.31–3.32, p = 0.002]. Female gender [SHR 1.48, 95% CI 1.03–2.12, 
p = 0.036] was associated with discontinuation due to AEs as well.
3.3.3. Discontinuation due to lack of effectiveness
Discontinuation rates due to lack of effectiveness were not signifi-
cantly different between age groups [Figure  2b], with an SHR of 
1.24 [95% CI 0.91–1.68] and 1.11 [95% CI 0.63–1.95] in the age 
groups 40–59 and ≥60, respectively. The only risk factor for discon-
tinuation due to lack of effectiveness was use of adalimumab, com-
pared with infliximab [SHR 1.54, 95% CI 1.15–2.07, p = 0.004].
3.4.  SAEs
All SAEs from start of anti-TNF therapy until 1 month after dis-
continuation are shown in Table 3. The incidence rate of different 
SAEs compared with the rate in the youngest age group, expressed 
as incidence rate ratios [IRR], are shown in Table 4. The overall 
SAE incidence rate in the ≥60 compared with the <40 age group 
was significantly higher [IRR 2.06, 95% CI 1.42–3.00, p < 0.001]. 
SAEs in the elderly patients are specified in Table 5.
Serious infections were documented in 42 patients. The serious 
infection rate [infections per 1000 py] was significantly higher in 
the elderly patient group [61.2 versus 16.0 and 12.4 per 1000 py, 
p <0.001]. Concomitant immunosuppressive comedication use at 
baseline did not result into a higher serious infection rate [IRR 0.95, 
95% CI 0.52–1.74, p = 0.857].
During anti-TNF therapy, five patients developed a malignancy. 
In the youngest group, one parotid tumour and one squamous cell 
carcinoma were detected. Two patients aged between 40 and 59 
Table 2. Reasons for anti-TNF discontinuation per age group.
Reason for discontinuation, All patients  
[n = 450]
1st anti-TNF < 40  
[n = 284]
1st anti-TNF 40–59  
[n = 133] 
1st anti-TNF ≥ 60  
[n = 33] 
p-value
AE, n [%] 128 [28.4] 77 [27.1] 38 [28.6] 13 [39.4] 0.330
 infection 22 11 9 2  
 infusion reaction 25 19 4 2
 dermatological side effect 19 15 3 1
 rheumatological side effect 19 12 6 1
 antidrug antibodies 11 3 5 3
 other AEs 32 17 11 4
Lack of effectiveness, n [%] 192 [42.7] 115 [40.5] 63 [47.4] 14 [42.4] 0.417
Remission, n [%] 62 [13.8] 43 [15.1] 18 [13.5] 1 [3.0] 0.066
Patients’ request, n [%] 11 [2.4] 9 [3.2] 2 [1.5] 0 [0.0] 0.564
Pregnancy, n [%] 14 [3.1] 14 [4.9] 0 [0.0] 0 [0.0] 0.007*
Other, n [%] 43 [9.6] 26 [9.2] 12 [9.0] 5 [15.2] 0.782
Bold entries are significant p-values. TNF, tumour necrosis factor; AE, adverse event; n, number.
*A p-value <0.05 was considered statistically significant.
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were diagnosed with breast cancer, and one elderly patient devel-
oped a squamous cell carcinoma.
3.5. Follow-up treatment
A total of 139/450 [30.9%] patients started a second anti-TNF agent 
within 1 year after discontinuation, respectively in 35.2%, 23.3%, 
and 24.2% of patients aged <40, 40–59, and ≥60 [p = 0.044].
4. Discussion
In this large multicentre cohort study, we found that older age [≥60] 
at the moment of starting a first anti-TNF agent was associated with 
more SAEs and serious infections, and increasing age was associated 
with a higher rate of treatment failure. In contrast, thiopurine use at 
start of anti-TNF was associated with a lower treatment failure rate.
Our results demonstrating higher treatment failure rates of anti-
TNF therapy in elderly IBD patients are in line with previous studies 
in small cohorts. Two retrospective single-centre studies reported 
higher discontinuation rates in elderly IBD patients who started anti-
TNF compared with younger IBD patients.11,12 In our cohort, AEs 
were an important reason for anti-TNF treatment failure in elderly 
patients. Moreover, there was a clear trend towards higher discon-
tinuation rates due to AEs in elderly patients compared with younger 
patients, although this did not reach statistical significance.
In our cohort, elderly patients had a higher serious infection rate 
[61.2 versus 16.0 and 12.4 per 1000 py]. Likewise, higher serious in-
fection rates [92 versus 31 per 1000 py] were reported in elderly IBD 
patients on anti-TNF therapy in a retrospective cohort study.11 The 
higher infection rate in the elderly on anti-TNF may be explained 
by the fact that older age itself is an independent risk factor for op-
portunistic infections [OI] and OI-related AEs in UC.15,16 The overall 
serious infection rate of 17 per 1000 py in our total cohort is in line 
with a French population-based study and the Treat registry, which 
reported rates of respectively 19 and 22 per 1000 py.17,18 The serious 
infection rate was not affected by concomitant co-medication use, 
in line with the results of the SONIC trial.19 In addition, we ob-
served only a limited number of malignancies during anti-TNF treat-
ment. Indeed, several studies previously reported no increased risk of 
malignancies in anti-TNF treated patients in general.20 However, the 
required follow-up for detection of malignancies may be longer than 
the follow-up time in our study [mean 46 months].
Concomitant thiopurine use was associated with a reduced 
risk of treatment failure. Previous studies reported conflicting re-
sults regarding the impact of co-medication on anti-TNF continu-
ation. Several studies reported co-medication to be associated with 
successful continuation of anti-TNF,19,21,22 and two studies found 
azathioprine combination therapy to be associated with anti-TNF 
cessation.12,23 Potential explanations for the lower risk of anti-TNF 
treatment failure in patients with combination therapy may be the 
suppression of immunogenicity, and the improved control of inflam-
mation with combination versus monotherapy.19 The only predictor 
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Figure 1. Cumulative incidence function of discontinuation due to adverse 
events or lack of effectiveness in patients who started anti-tumour necrosis 
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Figure 2. a: Cumulative incidence function of discontinuation due to adverse 
events in patients who started anti- tumour necrosis factor [TNF] at age 
<40/40–59/≥60 as estimated by the competing risk regression model. b: 
Cumulative incidence function of discontinuation due to lack of effectiveness 
in patients who started anti-TNF at age <40/40–59/≥60 as estimated by the 
competing risk regression model.
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compared with infliximab use. It was previously described that the 
median time to secondary loss of response was longer in infliximab- 
versus adalimumab-treated CD patients.24 In addition, a more recent 
systematic review reported infliximab to be superior to adalimumab 
in UC patients in inducing mucosal healing.25 Unfortunately, no 
head-to-head trials are available between infliximab and adalimumab 
to further explore these observations.
Our results provide more insight into the real-world experience 
of elderly patients on anti-TNF, and may have important implica-
tions for clinical practice. The higher rate of discontinuation due to 
treatment failure as well as the higher serious infection rate underline 
the need for close monitoring for early detection and management 
of [S]AEs in this patient category. Nevertheless, in clinical practice, 
not only the potential risks of AEs associated with anti-TNF treat-
ment but also the risks associated with alternative treatments such as 
other biologics or surgery should be considered.
The strengths of our study include the large number of patients 
on anti-TNF [n = 895], the multicentre setting including both 
an academic and four non-academic centres, and the long-term 
follow-up. In addition, this is the first study specifically evaluating 
treatment failure defined as discontinuation due to AEs or lack 
of effectiveness in patients in different age categories, while cor-
recting for competing risks. The importance of the correct statis-
tical method is illustrated by the fact that higher age was associated 
with discontinuation due to treatment failure in the competing risk 
model, whereas we did not observe differences in discontinuation 
rates when stopping due to remission was not regarded as a com-
peting risk [Supplementary Figure 1]. Competing risks should be 
considered in future analyses of treatment discontinuation, as dis-
continuation due to remission is a distinct clinical strategy in cur-
rent guidelines.26–28
This study also comes with limitations. First, there might be 
selection bias in patients who received anti-TNF, especially in the 





1st anti-TNF < 40   
[n = 546]   
Follow-up years = 1770
1st anti-TNF 40–59   
[n = 268]   
Follow-up years = 687
1st anti-TNF ≥ 60   
[n = 81]   
Follow-up years = 147
Number Number SAE rate /1000 py Number SAE rate /1000 py Number SAE rate /1000 py
Infection 42 22 12.4 11 16.0 9 61.2
Disease activity 96 65 36.7 25 36.4 6 40.8
Malignancy 6 3 1.7 2 2.9 1 6.8
Allergic reaction 7 5 2.8 0 0.0 2 13.6
Other 47 27 15.3 15 21.8 5 34.0
Hospitalisation 92 65 36.7 18 26.2 9 61.2
TNF, tumour necrosis factor; SAE, serious adverse event; py, patient-years; n, number.
Table 4. SAE incidence rate ratios in age group 40–59 and ≥60 compared with age group <40.
SAE 1st anti-TNF 40–59   
[n = 268]
1st anti-TNF ≥ 60   
[n = 81]
 IRR + 95%CI p-value IRR + 95% CI p-value
Total 0.98, 0.74–1.28 p = 0.871 2.06, 1.42–3.00 p <0.001*
Infection 1.29, 0.62–2.66 p = 0.494 4.92, 2.27–10.69 p <0.001*
Disease activity 0.99, 0.62–1.57 p = 0.967 1.11, 0.48–2.56 p = 0.805
Malignancy 1.72,0.29–10.27 p = 0.554 4.01,0.42–38.56 p = 0.229
Allergic reaction - p = 0.992 4.81, 0.93–24.81 p = 0.060
Other 1.43, 0.76–2.69 p = 0.266 2.23, 0.86–5.79 p = 0.100
Hospitalisation 0.61, 0.36–1.03 p = 0.065 1.43, 0.71–2.87 p = 0.316
Bold entries are significant p-values. TNF, tumour necrosis factor; SAE, serious adverse event; IRR, incidence rate ratio; n, number; CI, confidence interval.
*A p-value <0.05 was considered statistically significant
Table 5. SAEs in IBD patients aged ≥60.




- urinary sepsis 3
- cholecystitis 1
- bacteraemia during active disease 1
Disease activity  
- partial colectomy 1
- resection neoterminal ileum 1
- dehydration, high-output stoma 1
- abdominal pain 2
Malignancy  
- squamous cell carcinoma 1
Allergic reaction  




- foraminotomy L5 1
- inguinal hernia 1
- total hip prosthesis 1
- small cerebral infarction 1
SAE, serious adverse events; IBD, inflammatory bowel disease; PJP, pneumo-
cystis jirovecii pneumonia.
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elderly. Since previous studies reported higher AE risks in elderly, 
clinicians might be inclined to only treat the elderly with the most 
severe IBD with anti-TNF. Indeed, it is known that anti-TNF is used 
relatively less in the elderly IBD patients.29,30 Second, this cautious 
attitude of clinicians is reflected in the relatively small number of 
elderly patients on anti-TNF in our cohort compared with younger 
patients. This imbalance could potentially have impacted on out-
comes. It may have contributed to the fact we did not observe a sig-
nificantly higher discontinuation rate due to AEs in elderly patients 
compared with younger patients. However, we still observed that 
an increasing age was significantly associated with a higher risk of 
treatment failure. Third, we did not match elderly IBD patients to 
younger IBD patients on several potential confounding characteris-
tics such as disease duration and previous surgery.31,32 However, we 
did not observe an association between disease duration or surgery 
with treatment failure rates.
In conclusion, in this large multicentre cohort, we found that 
patients aged ≥60  years starting a first anti-TNF agent are at 
 increased risk of stopping anti-TNF due to AEs or lack of effective-
ness, compared with patients <60 years. Elderly IBD  patients had 
a higher SAE and serious infection rate. Furthermore,  concomitant 
thiopurine use was associated with a reduced risk of treatment 
failure. These findings support tight monitoring and timely man-
agement of [S]AEs when starting anti-TNF in elderly IBD patients.
Funding
Funding for the development and implementation of IBDREAM was obtained 
from the Netherlands Organisation for Health Research and Development 
(ZonMW, grant number 836042002).
Conflict of Interest
FH has served on advisory boards, or as speaker, or consultant for Abbvie, 
Celgene, Janssen Cilag, MSD, Takeda, Celltrion, Teva, Sandoz, and Dr Falk, 
and has received unrestricted grants from Dr Falk, Janssen-Cilag, Abbvie. JJ 
has served on advisory boards, or as speaker, or consultant for Abbvie, Amgen, 
Ferring, Fresenius, Janssen, MSD, Pfizer, Takeda. RW has participated in ad-
visory boards, or as a speaker, or consultant for the following companies: 
Abbvie, Janssen.
Acknowledgments
We thank all patients, research nurses and inflammatory bowel  disease gastro-
enterologists of the five departments of gastroenterology and hepatology in 
The Netherlands for their participation in the data collection.
Author Contributions
No additional writing assistance was used for this manuscript. MJ, LS, BR, 
NB, MR, TR, RW, JJ, and FH all contributed to the design of the study. MJ, 
FH, MR, TR, RW, and JJ included patients in IBDREAM. LS and MJ collected 
data; MJ, LS, and BR analysed the data. NB assisted in statistical analysis. 
LS and MJ drafted the manuscript. FH, NB, MR, TH, RW, and BR critically 
revised the manuscript for important intellectual content. All authors have ap-
proved the final version of this manuscript.
Supplementary Data
Supplementary data are available at ECCO-JCC online.
References
 1. Kaplan GG, Ng SC. Understanding and preventing the global increase of 
inflammatory bowel disease. Gastroenterology 2017;152:313–21.e2.
 2. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a 
network meta-analysis and Cochrane overview. Cochrane Database Syst 
Rev 2011:CD008794.
 3. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mor-
tality in patients with Crohn’s disease: more than 5 years of follow-up in 
the TREAT™ registry. Am J Gastroenterol 2012;107:1409–22.
 4. Gionchetti  P, Gomollón  F, et  al.; European Crohn’s and Colitis 
Organisation. Third European evidence-based consensus on the diagnosis 
and management of Crohn’s disease 2016. Part 1: diagnosis and medical 
management. J Crohns Colitis 2016;11:3–25.
 5. Harbord  M, Eliakim R, Bettenworth D, et  al.; European Crohn’s and 
Colitis Organisation. Third European evidence-based consensus on diag-
nosis and management of ulcerative colitis. Part 2: current management. J 
Crohns Colitis 2017;11:769–84.
 6. Siegel  CA, Marden  SM, Persing  SM, Larson  RJ, Sands  BE. Risk of 
lymphoma associated with combination anti-tumor necrosis factor and 
immunomodulator therapy for the treatment of Crohn’s disease: a meta-
analysis. Clin Gastroenterol Hepatol 2009;7:874–81.
 7. Osterman MT, Sandborn WJ, Colombel  JF, et  al. Increased risk of ma-
lignancy with adalimumab combination therapy, compared with mono-
therapy, for Crohn’s disease. Gastroenterology 2014;146:941–9.
 8. Ha CY, Katz S. Clinical implications of ageing for the management of IBD. 
Nat Rev Gastroenterol Hepatol 2014;11:128–38.
 9. Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflamma-
tory bowel disease in the elderly. Aliment Pharmacol Ther 2014;39:459–77.
 10. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent 
risk factor for severe infections and mortality in patients given anti-tumor 
necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol 
Hepatol 2011;9:30–5.
 11. Lobatón T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S. 
Efficacy and safety of anti-TNF therapy in elderly patients with inflamma-
tory bowel disease. Aliment Pharmacol Ther 2015;42:441–51.
 12. Desai A, Zator ZA, de Silva P, et al. Older age is associated with higher 
rate of discontinuation of anti-TNF therapy in patients with inflammatory 
bowel disease. Inflamm Bowel Dis 2013;19:309–15.
 13. Borren  NZ, Ananthakrishnan  AN. Safety of biologic therapy in older 
patients with immune-mediated diseases: a systematic review and meta-
analysis. Clin Gastroenterol Hepatol 2019;17:1736–43.e4.
 14. Sturm  A, Maaser  C, Mendall  M, et  al. European Crohn’s and Colitis 
Organisation topical review on IBD in the elderly. J Crohns Colitis 
2017;11:263–73.
 15. Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are 
associated with increased mortality in patients with inflammatory bowel 
diseases. J Crohns Colitis 2013;7:107–12.
 16. Ha CY. Risks of infection among the older inflammatory bowel disease 
patients. Curr Treat Options Gastroenterol 2014;12:283–91.
 17. Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. 
Risk of serious and opportunistic infections associated with treatment of 
inflammatory bowel diseases. Gastroenterology 2018;155:337–46.e10.
 18. Lichtenstein GR, Feagan BG, Cohen RD, et al. Infliximab for Crohn’s dis-
ease: more than 13 years of real-world experience. Inflamm Bowel Dis 
2018;24:490–501.
 19. Colombel  JF, Sandborn  WJ, Reinisch  W, et  al.; SONIC Study Group. 
Infliximab, azathioprine, or combination therapy for Crohn’s disease. N 
Engl J Med 2010;362:1383–95.
 20. Holmer A, Singh S. Overall and comparative safety of biologic and im-
munosuppressive therapy in inflammatory bowel diseases. Expert Rev 
Clin Immunol 2019;15:9596–9.
 21. Chen  C, Hartzema  AG, Xiao  H, et  al. Real-world pattern of biologic 
use in patients with inflammatory bowel disease: treatment persistence, 
switching, and importance of concurrent immunosuppressive therapy. 
Inflamm Bowel Dis 2019;25:1417–27.











trecht user on 17 M
ay 2021
 22. Singh S, Stitt LW, Zou G, et al. Early combined immunosuppression may 
be effective and safe in older patients with Crohn’s disease: post hoc ana-
lysis of REACT. Aliment Pharmacol Ther 2019;49:1188–94.
 23. Hisamatsu  T, Matsumoto  T, Watanabe  K, et  al. Concerns and side ef-
fects of azathioprine during adalimumab induction and maintenance 
therapy for Japanese patients with Crohn’s disease: a sub-analysis of a 
prospective randomized clinical trial [DIAMOND study]. J Crohns Colitis 
2019;13:1097–104.
 24. Ma C, Huang V, Fedorak DK, et al. Crohn’s disease outpatients treated 
with adalimumab have an earlier secondary loss of response and require-
ment for dose escalation compared with infliximab: a real-life cohort 
study. J Crohns Colitis 2014;8:1454–63.
 25. Cholapranee  A, Hazlewood  GS, Kaplan  GG, Peyrin-Biroulet  L, 
Ananthakrishnan AN. Systematic review with meta-analysis: comparative 
efficacy of biologics for induction and maintenance of mucosal healing in 
Crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol 
Ther 2017;45:1291–302.
 26. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission 
among patients with Crohn’s disease on antimetabolite therapy after 
infliximab therapy is stopped. Gastroenterology 2012;142:63–70.e5; 
quiz e31.
 27. Gisbert JP, Marín AC, Chaparro M. The risk of relapse after anti-TNF dis-
continuation in inflammatory bowel disease: systematic review and meta-
analysis. Am J Gastroenterol 2016;111:632–47.
 28. Casanova  MJ, Chaparro  M, García-Sánchez  V, et  al. Evolution after 
Anti-TNF discontinuation in patients with inflammatory bowel dis-
ease: a multicenter long-term follow-up study. Am J Gastroenterol 
2017;112:120–31.
 29. Johnson  SL, Bartels  CM, Palta  M, Thorpe  CT, Weiss  JM, Smith  MA. 
Biological and steroid use in relationship to quality measures in older pa-
tients with inflammatory bowel disease: a US Medicare cohort study. BMJ 
Open 2015;5:e008597.
 30. Everhov  ÅH, Halfvarson  J, Myrelid  P, et  al. Incidence and treatment 
of patients diagnosed with  inflammatory bowel diseases at 60  years or 
older in Sweden. Gastroenterology 2018;154:518–28.e15.
 31. Panaccione  R, Löfberg  R, Rutgeerts  P, et  al. Efficacy and safety of 
adalimumab by disease duration: analysis of pooled data from Crohn’s 
disease studies. J Crohns Colitis 2019;13:725–34.
 32. Loftus  EV Jr, Reinisch  W, Panaccione  R, et  al. Adalimumab effective-
ness up to six years in adalimumab-naive patients with Crohn’s dis-
ease: results of the PYRAMID registry. Inflamm Bowel Dis 2019;25: 
1522–31.











trecht user on 17 M
ay 2021
